-
-
-
公开(公告)号：KR20180044667A
公开(公告)日：2018-05-03
申请号：KR20160138467
申请日：2016-10-24
Applicant: 충남대학교산학협력단
IPC: C12Q1/68
CPC classification number: C12Q1/6883 , C12Q1/6886 , C12Q2600/136 , C12Q2600/178
Abstract: 본발명은마이크로 RNA를마커로이용한자가포식조절제의스크리닝방법에관한것으로, 보다상세하게는 (A) miRNA-144를발현하는세포또는조직에시험물질을처리하는단계; 및 (B) 상기시험물질이처리된세포또는조직에서 miRNA-144의발현을측정하는단계; 및 (C) 상기 (B) 단계에서측정된 miRNA-144의발현수준이시험물질을처리하지않은대조군에비해변화된경우자가포식조절제로판정하는단계;를포함하는것을특징으로하는자가포식조절제의스크리닝방법에관한것이다.
-
公开(公告)号：KR101706660B1
公开(公告)日：2017-02-21
申请号：KR1020140194037
申请日：2014-12-30
Applicant: 충남대학교산학협력단 , 한양대학교 에리카산학협력단
IPC: A61K31/7056 , A61K31/216 , A61K48/00 , A23L1/30
Abstract: 본발명은신장질환의예방및 치료용약학조성물에관한것으로, 보다상세하게는고아핵 수용체의일종인 SHP를유효성분으로포함하는신장질환예방및 치료용약학조성물에관한것이다.
Abstract translation: 本发明涉及用于预防或治疗肾病的药物组合物。 更具体地说，本发明涉及一种预防或治疗肾病的药物组合物，其含有作为孤儿核受体之一的小型二聚体配偶体（SHP）作为有效成分。
-
公开(公告)号：KR101572219B1
公开(公告)日：2015-11-30
申请号：KR1020130137700
申请日：2013-11-13
Applicant: 한국과학기술원 , 충남대학교산학협력단 , 한국기초과학지원연구원
CPC classification number: C12N15/1058 , C07K14/195 , C07K14/461 , C07K2318/20 , C12N15/1037 , C40B40/10
Abstract: 본발명은반복모듈을포함하는리피바디단백질의개량방법및 리피바디단백질개량을위한리피바디라이브러리를코딩하는뉴클레오티드라이브러리에관한것으로, 더욱자세하게는리피바디단백질을구성하는반복모듈을순차적으로변이시키는모듈진화방법을이용한리피바디단백질의개량방법및 상기단백질개량에사용되는리피바디라이브러리를코딩하는뉴클레오티드라이브러리에관한것이다. 본발명에따른모듈진화방법에의하면, 높은결합친화도를가지고이에따른특이도및 활성이증가된개량된리피바디단백질을스크리닝할수 있어, 타겟물질에대한억제제, 치료제및 분석수단으로사용되는리피바디를개발하는데에용이하다.
-
Patent Agency Ranking
公开(公告)号：KR1020150055397A
公开(公告)日：2015-05-21
申请号：KR1020130137700
申请日：2013-11-13
Applicant: 한국과학기술원 , 충남대학교산학협력단 , 한국기초과학지원연구원
CPC classification number: C12N15/1058 , C07K14/195 , C07K14/461 , C07K2318/20 , C12N15/1037 , C40B40/10
Abstract: 본발명은반복모듈을포함하는리피바디단백질의개량방법및 리피바디단백질개량을위한리피바디라이브러리를코딩하는뉴클레오티드라이브러리에관한것으로, 더욱자세하게는리피바디단백질을구성하는반복모듈을순차적으로변이시키는모듈진화방법을이용한리피바디단백질의개량방법및 상기단백질개량에사용되는리피바디라이브러리를코딩하는뉴클레오티드라이브러리에관한것이다. 본발명에따른모듈진화방법에의하면, 높은결합친화도를가지고이에따른특이도및 활성이증가된개량된리피바디단백질을스크리닝할수 있어, 타겟물질에대한억제제, 치료제및 분석수단으로사용되는리피바디를개발하는데에용이하다.
Abstract translation: 本发明涉及一种用于改进重复体蛋白质的方法，包括重复模块和用于改进重组体蛋白质的编码重复体的文库的核苷酸库编码方法，更具体地说，涉及通过使用用于连续改变重复模块的模块进化方法来改进重组体蛋白质的方法 重复体蛋白质和编码用于改善重组体蛋白质的重组体文库的核苷酸文库编码，其中允许模块进化方法筛选具有高结合亲和力并因此增加特异性和活性的改进的重组体蛋白质，从而用于开发所使用的重组体 用于靶物质的抑制剂，药物和分析工具。
-
公开(公告)号：KR101344025B1
公开(公告)日：2013-12-24
申请号：KR1020120022323
申请日：2012-03-05
Applicant: 충남대학교산학협력단
Abstract: 본발명은결핵균감염에의한치료제로사용하는항결핵제들의효능을간편하고빠르게스크리닝할수 있는방법에관한것으로, 보다상세하게는 (A) 대식세포에결핵균을감염시키는단계; (B) 결핵균이감염된대식세포에항결핵효능을측정하고자하는시료를처리하는단계; (C) 상기시료의처리에의한① 자가포식의유도여부, ②활성산소종의증가여부및 ③결핵균생존률의감소여부로구성되는군으로부터선택된하나이상을확인하는단계;를포함하여이루어지는것을특징으로하는항결핵제의스크리닝방법에관한것이다.
-
公开(公告)号：KR101344218B1
公开(公告)日：2013-12-20
申请号：KR1020130055030
申请日：2013-05-15
Applicant: 충남대학교산학협력단
IPC: A61K31/216 , A61P31/06
CPC classification number: A61K31/216
Abstract: The present invention relates to a pharmaceutical composition for treatment of tuberculosis containing fenofibrate. According to the present invention, the pharmaceutical composition for treatment of tuberculosis containing fenofibrate contains an active component as fenofibrate. The fenofibrate is used as a medicine for hyperlipemia.
Abstract translation: 本发明涉及用于治疗含有非诺贝特的结核病的药物组合物。 根据本发明，用于治疗含有非诺贝特的结核病的药物组合物含有作为非诺贝特的活性成分。 非诺贝特用作高脂血症药物。
-
公开(公告)号：KR1020130116797A
公开(公告)日：2013-10-24
申请号：KR1020130027015
申请日：2013-03-14
Applicant: 충남대학교산학협력단
IPC: G01N33/53 , C12Q1/02 , C12N5/0786
Abstract: PURPOSE: A reagent for diagnosis and follow-up study on type 2 diabetes and a test method including a measurement of IL-1 beta are provided to accurately diagnose type 2 diabetes with convenience and comfortableness. CONSTITUTION: A novel method for diagnosing type 2 diabetes comprises the steps of: inducing macrophage from monocytes collected from blood of a person who is suspected to have diabetes and culturing the macrophage; measuring the concentration of active IL-1 beta secreted from the cultured macrophage; and determining type 2 diabetes when the concentration of active IL-1 beta is over a predetermined level. A method for determining treatment effects on type 2 diabetes comprises the steps of: inducing macrophage from monocytes collected from a patient's blood with a type 2 diabetes during treatment and culturing the macrophage; measuring the concentration of active IL-1 beta secreted from the cultured macrophage; and determining that a treatment has an effect on the patient when the concentration of active IL-1 beta is less than a predetermined level. [Reference numerals] (A) Patient with type 2 diabete before meformin treatment; (B) Patient with type 2 diabete after meformin treatment; (H) Ordinary person
Abstract translation: 目的：提供一种用于2型糖尿病诊断和随访研究的试剂和包括测量IL-1β的测试方法，以便于方便和舒适地准确诊断2型糖尿病。 构成：用于诊断2型糖尿病的新方法包括以下步骤：从怀疑患有糖尿病并培养巨噬细胞的人的血液中收集的单核细胞诱导巨噬细胞; 测量从培养的巨噬细胞分泌的活性IL-1β的浓度; 并且当活性IL-1β的浓度超过预定水平时确定2型糖尿病。 用于确定对2型糖尿病的治疗效果的方法包括以下步骤：在处理和培养巨噬细胞期间从患有血清的2型糖尿病中收集的单核细胞诱导巨噬细胞; 测量从培养的巨噬细胞分泌的活性IL-1β的浓度; 并且当活性IL-1β的浓度小于预定水平时，确定治疗对患者有影响。 （附图标记）（A）甲泼尼龙治疗前2型糖尿病患者; （B）甲吡啶治疗后2型糖尿病患者; （H）普通人
-
公开(公告)号：KR1020130101295A
公开(公告)日：2013-09-13
申请号：KR1020120022323
申请日：2012-03-05
Applicant: 충남대학교산학협력단
Abstract: PURPOSE: A method for screening an anti-tuberculosis drug is provided to quickly and simply screen an anti-tuberculosis drug, thereby developing a novel drug and a novel formulation and managing product quality. CONSTITUTION: A method for screening an anti-tuberculosis drug comprises the steps of: infecting tuberculous bacillus to macrophage; treating the macrophage with a sample; and identifying the induction of autophagy, the increase of reactive oxygen species, and the reduction of tuberculous bacillus survival rate.
Abstract translation: 目的：提供一种筛选抗结核药物的方法，快速，简便地筛选抗结核药物，从而开发新型药物和新型配方，并管理产品质量。 构成：筛选抗结核药物的方法包括以下步骤：感染结核杆菌至巨噬细胞; 用样品处理巨噬细胞; 并鉴定自噬的诱导，活性氧的增加以及结核杆菌存活率的降低。
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.028 seconds)
